3 Healthcare Stocks with Strong Buy Ratings and Double-Digit Upside
BioMarin Pharmaceutical ($BMRN), Boston Scientific ($BSX), and Ionis Pharmaceuticals ($IONS) are three healthcare stocks with Strong Buy ratings an...
Ionis Pharmaceuticals Inc (IONS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Squarepoint Ops LLC Maxime Fortin (Cio) | 1,123,262 | $50,153,648 | +927% | 0.06% |
| 2. | Renaissance Technologies Jim Simons | 354,214 | $15,815,655 | -37% | 0.02% |
| 3. | Fisher Asset Management Ken Fisher | 182,997 | $8,170,858 | +34% | 0% |
| 4. | Winton Capital Management David Harding | 127,350 | $5,686,178 | 0.22% | |
| 5. | Motley Fool Asset Management Bryan Hinmon | 83,753 | $3,739,571 | 0.14% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $51.60 | 5,000 | $258,000.00 | 24,000 | 2026-07-31 | Filing | |
| $53.38 | 15,000 | $800,700.00 | 19,000 | 2026-07-30 | Filing | |
| $31.86 | 15,000 | $477,900.00 | 50,219 | 2025-05-01 | Filing | |
| $36.23 | 2,500 | $90,583.00 | 35,219 | 2024-12-23 | Filing | |
| $36.20 | 2,500 | $90,495.75 | 32,719 | 2024-12-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.54 | 1,357 | $59,081.88 | 17,811 | 2026-10-16 | Filing | |
| $43.54 | 53 | $2,307.56 | 390 | 2026-10-16 | Filing | |
| $85.46 | 15,000 | $1,281,930.00 | 0 | 2026-07-07 | Filing | |
| $83.58 | 5,536 | $462,693.34 | 75,018 | 2026-07-07 | Filing | |
| $85.42 | 10,111 | $863,637.13 | 3,811 | 2026-07-07 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 24,740,108 | $1,104,645,822 | 0.05% | |
| 2. | AmundiBOND | 3,450,000 | $377,640,391 | 0.08% |
| 3. | 5,710,900 | $254,977,710 | 0.01% | |
| 4. | 3,277,569 | $146,379,160 | 0.01% | |
| 5. | 1,944,020 | $87,249,218 | 0.08% |
News See All
AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
AI startup BioinvestGPT predicted the failure of Novartis AG’s ($NVS) experimental muscular dystrophy drug months before a disappointing Phase 3 re...
Failure of Novartis' Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker.
Novartis (NVS) and Ionis (IONS)' Big Cholesterol Bet Comes Up Short in Late-Stage Trial
On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis Pharmaceuticals, Inc.
Novartis' Failed Cholesterol Drug Trial Sends Ionis and Amgen Tumbling
Few concepts in cardiovascular medicine have sparked as much optimism as Lp(a)-lowering medications.
Ionis Has Its First Neurology Launch, But Can Zanvastro Justify Its $285,000 Price?
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has turned decades of RNA research into its first independently launched neurology medicine.
BofA Sees Limited Damage from Novartis (NVS)’ Pelacarsen Miss While Citi Looks Towards Ionis (IONS)
Novartis AG’s (NYSE:NVS) pelacarsen failed an important test.
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss
Ionis Pharmaceuticals, Inc. ($IONS) shares dropped about 10% in premarket trading after a large cardiovascular trial of pelacarsen, a drug develope...
Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints
Novartis ($NVS) stock plunged about 13% in Tuesday’s pre-market trading as the Swiss drugmaker’s experimental drug, del-desiran, for a muscle-wasti...
Ionis Pharmaceuticals (IONS) Gains First-Mover Advantage with FDA Approval of Rare Brain Disease Drug
The U.S. FDA has approved Ionis Pharmaceuticals, Inc.
Hedge Fund Resource Center